**Supplementary Materials**

**Table 1.** REMARK profile – double expression of MYC/BCL2 to National Comprehensive Cancer Network Internal Prognostic Index.

|  |
| --- |
| a) Patients and variables  |
| Study and marker | **Remarks** |
| Marker  | M=Double expression of MYC and BCL2 proteins (DE: MYC ≥ 40% and BCL2 ≥ 50%, non-DE: other than DE) |
| Further variable | v=NCCN-IPI  |
| Patients | **n** | **Remarks** |
| Assessed for eligibility | 319 | **Disease**: diffuse large B-cell lymphoma**Patient source**: Ramathibodi Hospital and Thammasat University Hospital from 1 January 2014 to 31 Jan 2018 |
| Excluded | 208 | 133 no R-CHOP, 75 no MYC and BCL2  |
| Included | 111 | Age ≥18 years old, R-CHOP, MYC/BCL2 result  |
| Outcome events | 51 | Progression: refractory disease or relapse or death from any cause |
| b) Statistical analysis |
| Analysis (A) | **n** | **Events** | **Outcomes** | **Variables considered** | **Results/remarks** |
| IDA: Descriptive | 111 | 51 | Progression | DE | Fig. 1, Table 2, Fig. 2 |
| A1: Univariable  Unadjusted A2: Adjusted | 111111111111 | 51475151 | PFS5-y PFSPFSPFS  | M, v1 M, v1MM, v1 | Fig. 3 (KM)Table 3 (Probability)Table 4 (HR)Table 4 (Adjusted HR and c-index of NCCN-IPI with DE) |

A: analysis; c-index: concordance index; DE: double expression of MYC and BCL2; ECOG: Eastern Cooperative Oncology Group Performance Status; HR: hazard ratio; IDA: initial data analysis; KM: Kaplan–Meier survival curves; LDH: lactate dehydrogenase; M: marker; NCCN-IPI: National Comprehensive Cancer Network Internal Prognostic Index; PFS: progression-free survival; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; v: variable.